[8-K] AIM ImmunoTech Inc. Reports Material Event

Rhea-AI Filing Summary

AIM ImmunoTech received a warning notification from NYSE American on June 17, 2025, regarding non-compliance with minimum stockholders' equity requirements. The company reported a stockholders' deficit of -$3.9 million as of March 31, 2025, falling short of the required:

• $4.0 million minimum for companies with losses in 3 of 4 recent fiscal years
• $6.0 million minimum for companies with losses in 5 most recent fiscal years

This follows a previous warning from December 17, 2024. The NYSE American has accepted AIM's compliance plan, giving the company until June 11, 2026 to meet requirements. Trading continues under symbol "AIM" without interruption, and the warning does not affect business operations or SEC reporting requirements. The company's stock resumed trading on NYSE American on June 17, 2025.

Positive

• NYSE American has accepted company's compliance plan, giving AIM until June 11, 2026 to regain compliance
• Company's stock continues trading on NYSE American without interruption

Negative

• Company reported stockholders' deficit of -$3.9M as of March 31, 2025, failing to meet NYSE American's minimum equity requirements
• Company has reported losses for five consecutive fiscal years through December 31, 2024
• Second NYSE American warning received in 6 months (previous warning in December 2024) for continued listing standard violations

Insights

Securities Compliance Analyst

AIM ImmunoTech received another NYSE American warning for insufficient stockholders' equity, with continued listing at risk despite remediation plan.

AIM ImmunoTech has received a second warning notification from NYSE American regarding its failure to meet minimum stockholders' equity requirements. The company currently has a stockholders' deficit of negative $3.9 million, falling significantly short of the $4 million minimum required for companies with losses in three of four recent fiscal years and the $6 million threshold for those with losses in all five recent fiscal years. Both conditions apply to AIM, which has reported losses consistently through December 31, 2024.

This represents a continued non-compliance issue, as NYSE American previously issued a warning for the same deficiency in December 2024. While concerning, the exchange has already accepted AIM's compliance plan submitted in February 2025, giving the company until June 11, 2026 to regain compliance. This extended remediation timeline remains intact despite the new warning.

Importantly, AIM's common stock continues trading normally on NYSE American under symbol "AIM" with no immediate trading restrictions. This filing represents a disclosure obligation rather than a new development in the delisting process. The company must execute its accepted remediation plan to avoid potential future delisting actions as the June 2026 deadline approaches. The substantial negative equity position suggests significant financial restructuring will be necessary to achieve compliance.

false 0000946644 0000946644 2025-06-17 2025-06-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 17, 2025

AIM IMMUNOTECH INC.

(Exact name of registrant as specified in its charter)

Delaware		001-27072		52-0845822
(state or other jurisdiction		(Commission		(IRS Employer
of incorporation)		File Number)		Identification No.)

2117 SW Highway 484, Ocala FL		34473
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (352) 448-7797

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.001 per share		AIM		NYSE American

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On June 17, 2025, AIM ImmunoTech Inc. (the “Company”) received a warning notification (the “Letter”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”) requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively. As of March 31, 2025, the Company had a stockholders’ deficit of negative $3.9 million and has had losses in the most recent five fiscal years ended December 31, 2024.

The NYSE American previously issued a warning on December 17, 2024 for the same reasons and has issued the Letter because the deficiency remains as of March 31, 2025 when the Company filed its quarterly report on Form 10-Q for the first quarter of fiscal 2025.

On February 26, 2025, the NYSE American accepted a plan (the “Plan”) submitted by the Company to regain compliance by June 11, 2026. Accordingly, the Company still has until June 11, 2026 to regain compliance.

The Company’s common stock recommenced trading on the NYSE American on June 17, 2025 under the symbol “AIM”.

The Letter in no way has any effect on such trading and does not affect the Company’s business, operations or reporting requirements with the U.S. Securities and Exchange Commission.

Item 8.01 Other Events

On June 20, 2025, the Company issued a press release announcing its receipt of the Letter. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

Cautionary Statement Regarding Forward-Looking Statements

This current report, including exhibit 99.1, contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. There can be no assurance that the Company will be able to achieve compliance with the NYSE American’s continued listing standards within the required timeframe. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this current report. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are filed herewith:

Exhibit Number		Description
99.1		Press Release dated June 20, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AIM ImmunoTech Inc.
Date: June 20, 2025	By	/s/ Thomas K. Equels
		Thomas K. Equels, CEO

FAQ

Why did AIM ImmunoTech (AIM) receive a NYSE American warning notice in June 2025?

AIM ImmunoTech received a warning notice on June 17, 2025, because it failed to meet NYSE American's minimum stockholders' equity requirements. The company reported a stockholders' deficit of negative $3.9 million as of March 31, 2025, and has had losses in the five most recent fiscal years through December 31, 2024.

What are the specific NYSE American listing requirements that AIM failed to meet?

AIM failed to meet two requirements under Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide: 1) maintaining stockholders' equity of $4.0 million or more if reporting losses in 3 of 4 recent fiscal years, and 2) maintaining $6.0 million or more if reporting losses in 5 most recent fiscal years.

When does AIM need to regain compliance with NYSE American listing standards?

AIM has until June 11, 2026, to regain compliance with NYSE American listing standards. The exchange previously accepted AIM's compliance plan on February 26, 2025, giving the company this deadline to meet requirements.

Will AIM's NYSE American listing warning affect its stock trading or operations?

No, the warning notice does not affect AIM's stock trading or operations. The company's common stock continues trading on NYSE American under the symbol 'AIM', and the notice does not impact its business operations or SEC reporting requirements.

What was AIM's stockholders' equity position as of Q1 2025?

As of March 31, 2025 (Q1 2025), AIM reported a stockholders' deficit of negative $3.9 million, falling significantly below the NYSE American's minimum requirements of $4.0 million or $6.0 million depending on loss history.